Roche Release: 454 Life Sciences Sequencing Identifies Early Stage HIV Drug Resistance-- Low-level Mutations may have Significant Impact on Clinical Outcomes

BRANFORD, Conn--(BUSINESS WIRE)--A research study published online this week in the Journal of Infectious Disease reports that HIV resistance mutations present in as little as 1% of the viral population have a significant impact on clinical outcomes. The paper outlines the results of a collaborative study between 454 Life Sciences, a Roche company, and a Yale School of Medicine researcher that used 454 Sequencing Systems to identify previously undetectable drug resistant HIV variants in research samples from an earlier performed clinical trial, called the FIRST Study (1).

Back to news